What is the latest domestic market price of trametinib in 2025?

Trametinib is a selective MEK1/2 inhibitor that targets the MAPK pathway and is widely used in patients with a variety of malignant tumors carrying BRAF V600E or V600K mutations. Since its launch, it has been approved in many countries around the world and has gradually been included in the recommendations of domestic clinical guidelines. It has shown clear efficacy in the fields of advanced melanoma, non-small cell lung cancer, and certain thyroid cancers. Trametinib is usually used in combination with the BRAF inhibitor dabrafenib to inhibit the growth of cancer cells through a dual-target mechanism, improve disease control rates and delay the occurrence of drug resistance.

In terms of price, the original drug of trametinib has officially entered the Chinese market. The current common specifications are2 mg × 30 tablets and 0.5 mg × 30 tablets. After medical insurance negotiation, patients who meet specific indications can receive partial or full reimbursement through medical insurance channels, which greatly alleviates the economic pressure caused by targeted therapy. The price is about 10,000 yuan per box. It should be noted that the use of medical insurance must strictly follow the indications and diagnosis and treatment paths defined in the national or provincial medical insurance catalog, and a prescription must be issued by a designated hospital.

In overseas markets, the price of trametinib fluctuates greatly. For example, in Türkiye, the price of the original version is more affordable than in China, about 7,000 yuan per box. Exchange rate fluctuations may lead to price adjustments. In addition, countries such as Laos also produce generic versions, whose main pharmaceutical ingredients are the same as those of the original ones, and the price may be as low as about 1,000 yuan. The purchase channels for such products need to be carefully screened to ensure the quality and legality of the source, and to avoid affecting the efficacy due to improper storage conditions or inconsistent versions.

In summary, trametinib has become an important treatment option for a variety of BRAF mutation-related tumors due to its precise targeting mechanism. Domestic original drugs have entered the medical insurance system, and the price burden has been significantly improved; while overseas versions and generic drugs provide more choices, which is of certain practical significance especially for patients with limited financial conditions.

Reference materials:https://go.drugbank.com/drugs/DB08911